This Crypto Outperformed Bitcoin, Ethereum, Dogecoin Last Week With A Whopping 35% Gain

Fantom (CRYPTO: FTM) has rallied over 35% in the past seven days, trading at $0.2461, recorded on Monday at 12 a.m. EST.

Fantom (CRYPTO: FTM) has rallied over 35% in the past seven days, trading at $0.2461, recorded on Monday at 12 a.m. EST.

What Happened: Apex cryptocurrency Bitcoin (CRYPTO: BTC) is up 6.56%, reaching the $17,000 mark as investor sentiment was largely unchanged going into the fresh trading week. Ethereum (CRYPTO: ETH) is up 10.21%, and Dogecoin (CRYPTO: DOGE) by 9.88% in the last seven days.

Cryptocurrency Weekly Performance Price (Monday, 12.00 am EST)
Fantom +35% $0.24
GMX Token +29% $54.65
EthereumPOW +24.40% $4.03
ImmutableX +20.81% $0.50
THORChain +20.30% $1.39

The price boost for FTM came after the Fantom Foundation revealed its financial records. The documents showed that the organization has been obtaining steady gains and has 30 years of financial security without having to dispose of any of its FTM tokens. On Nov. 28, Andre Cronje, the Architect of Fantom Foundation, said that Fantom Foundation owned $340 million in digital assets and had produced more than $10 million in yearly income.

See More: Best Crypto Apps

GMX Token (CRYPTO: GMX), the in-house token of the GMX  exchange, is second on the list gaining 29% last week. 

The third on the list is EthereumPOW (CRYPTO: ETHW) which recorded a 24.40% spike. The rally was seen after ETHW Foundation said in a tweet that two-and-a-half months after the fork over 86 million active addresses hold the forked crypto.

ImmutableX (CRYPTO: IMX) is fourth on the list, gaining 20.81%, and THORChain (CRYPTO: RUNE) was last on the list, up 20.30%, in the past seven days.

Read Next: Coinbase CEO Says Sam Bankman-Fried’s Hedge Fund Used $8B Of Stolen Customer Money: ‘Even The Most Gullible Person Shouldn’t Believe…’

Total
0
Shares
Related Posts
Read More

Veru To Host Investor Call On January 4th, 2024 To Discuss Recent Financing And Strategy To Prioritize The Development Of Enobosarm As A Combination Treatment To Prevent Muscle Loss And Augment Fat Loss Associated With Weight Loss GLP-1 Drugs

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today

VERU